Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson’s disease

@article{CalandraBuonaura2015PharmacodynamicsOA,
  title={Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson’s disease},
  author={Giovanna Calandra-Buonaura and Andrea Doria and Giovanna Lopane and Pietro Guaraldi and Sabina Capellari and Paolo Martinelli and Pietro Cortelli and Manuela Contin},
  journal={Journal of Neurology},
  year={2015},
  volume={263},
  pages={250-256}
}
The differential diagnosis between multiple system atrophy with predominant parkinsonism (MSA-P) and Parkinson’s disease (PD) may be challenging at disease onset. Levodopa responsiveness helps distinguish the two groups, but studies evaluating this issue using objective standardized tests are scanty. We retrospectively examined the extent of levodopa response by an objective kinetic-dynamic test in a series of patients prospectively followed up for a parkinsonian syndrome and eventually… 
11 Citations
Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort
TLDR
The estimation of 3 h AUC_ETap after a subacute low LD dose proved a reliable, objective tool to assess LD motor response in a cohort of patients.
Diagnosis of multiple system atrophy
TLDR
Despite advances in the diagnostic tools for MSA in recent years and the availability of consensus criteria for clinical diagnosis, the diagnostic accuracy of MSA remains sub-optimal.
Multiple System Atrophy – Cerebellar Type: Clinical Picture and Treatment of an Often-Overlooked Disorder
TLDR
The therapeutic strategies as well as the clinical picture and the actualized treatment modalities of the MSA cerebellar type are underlined, and the treatment of MSA-C is mainly symptomatic; there are not many studies on M SA-C.
Early recognition and diagnosis of multiple system atrophy: best practice and emerging concepts
TLDR
The authors reappraised the main clinical, neurophysiological, imaging, genetic, and laboratory evidence to help in the early diagnosis of MSA in the clinical and in the research settings and summarized the unmet needs.
Early stridor onset and stridor treatment predict survival in 136 patients with MSA
TLDR
It is demonstrated that early stridor onset is an independent predictor for shorter survival and that tracheostomy could controlstridor, influencing disease duration.
Supervised versus unsupervised technology-based levodopa monitoring in Parkinson’s disease: an intrasubject comparison
TLDR
This study is the first to explore the potential of unsupervised technology-based objective motor and non-motor tasks to monitor subacute LD dosing effects in PD patients, and the results are promising for future telemedicine applications.
The natural history of idiopathic autonomic failure
TLDR
It is demonstrated that specific clinical and instrumental features entail an increased probability of phenoconversion, which could contribute to a better definition of the nature of IAF and to the identification of early markers of Phenoconversion.
A Longitudinal Skin Biopsy Study of Phosphorylated Alpha-Synuclein in a Patient With Parkinson Disease and Orthostatic Hypotension.
TLDR
Assessment of phosphorylated α-synuclein deposits in a patient affected by early stage Parkinson disease and orthostatic hypotension through a longitudinal skin biopsy study found widespread p-syn spatial diffusion from deep autonomic dermis nerve bundles to autonomic terminals, suggesting a centrifugal spread of p- syn from ganglia to the innervation target structures.
Review: Novel treatment strategies targeting alpha‐synuclein in multiple system atrophy as a model of synucleinopathy
TLDR
The clinical and pathological attributes of MSA make this disorder an excellent candidate as a synucleinopathy model for accelerated drug development, and research areas for potential improvement in MSA drug discovery are enumerated.
...
1
2
...

References

SHOWING 1-10 OF 33 REFERENCES
A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease
TLDR
Results are in keeping with PET findings on the objective assessment of idiopathic parkinsonism evolution, and they support the suggestion that levodopa pharmacodynamic modeling may offer a practical clinical tool to assess indirectly the functional integrity of the nigrostriatal dopaminergic system over time in parkinsonian patients.
Assessing dopaminergic function in Parkinson’s disease: levodopa kinetic-dynamic modeling and SPECT
TLDR
Levodopa PK-PD modeling can be a practical clinical tool indirectly assessing the functional integrity of the nigrostriatal dopaminergic system in PD patients as well as direct SPECT measures of presynaptic dopamine transporters homeostasis.
Levodopa Therapy Monitoring in Patients With Parkinson Disease: a Kinetic–Dynamic Approach
TLDR
Knowledge of individual patients' kinetic–dynamic variables can help the physician assess patients' clinical needs objectively and optimize levodopa dosing according to disease progression and support a stratification of patients with Parkinson disease according to kinetic-dynamic modeling.
Levodopa and the progression of Parkinson's disease.
TLDR
The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on the symptoms of the disease, and the neuroimaging data suggest either thatlevodopa accelerates the loss of nigrostriatal dopamine nerve terminals or that its pharmacologic effects modify the dopamine transporter.
Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
TLDR
The progressive shortening of motor response after both apomorphine and levodopa suggests that pharmacodynamic factors play an important part in determining the duration of motorresponse and argues against altered central pharmacokinetics of levodOPA being principally responsible for the on-off effect.
The dopaminergic response in multiple system atrophy.
TLDR
The occurrence of levodopa-induced dyskinesias without a concomitant motor response and delayed deterioration several days afterlevodopa withdrawal may be more typical of patients with MSA than Parkinson's disease.
Response to L-DOPA in multiple system atrophy.
TLDR
Motor response was consistently good in all PD patients, but only four MSA patients had a (moderate) response to L-DOPA, and Pharmacokinetic parameters did not differ between the groups.
Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry
TLDR
This largest clinical series of MSA patients reported so far shows that the disease presents uniformly across Europe, and the observed differences in diagnostic and therapeutic management including lack of therapy for dysautonomia emphasize the need for future guidelines in these areas.
Multiple system atrophy: A review of 203 pathologically proven cases
TLDR
Characteristic glial and/or neuronal cytoplasmic inclusions were identified in all cases in which they were sought, irrespective of clinical presentation, and an association of postural hypotension with intermediolateral cell column degeneration was confirmed.
The natural history of multiple system atrophy: a prospective European cohort study
TLDR
The final analysis of a prospective multicentre study by the European MSA Study Group provides new insights into the evolution of MSA based on a follow-up period that exceeds that of previous studies.
...
1
2
3
4
...